🔍 Definition
Pediatric risk adjustment refers to the statistical process of modifying capitation payments or predicted healthcare expenditures to account for the health status and expected costs of children enrolled in managed care plans. Unlike adult Medicare risk adjustment (which uses CMS-HCC v28), pediatric populations are primarily risk-adjusted under two major frameworks:
- CDPS+Rx (Chronic Illness and Disability Payment System with Rx) — the dominant model used by state Medicaid programs for children, developed at UC San Diego. It groups diagnoses into clinical categories and assigns relative weights to predict costs for Medicaid managed care enrollees, including children with special health care needs (CSHCN).
- HHS-HCC (Hierarchical Condition Categories for the ACA exchanges) — used under the Affordable Care Act (ACA) risk adjustment program for individual and small group commercial and exchange plans. This model includes a separate child age factor applied to condition weights, making it the primary risk adjustment model for children enrolled in ACA Marketplace plans.
Pediatric-specific conditions that risk adjust are ICD-10-CM-coded diagnoses that, when documented and coded accurately, trigger a HHS-HCC category or CDPS/Medicaid category assignment, thereby increasing the risk score and expected payment for that child’s health plan. Accurate documentation directly affects plan revenue, quality measurement, and downstream resource allocation for complex pediatric patients.
CMS-HCC v28 (the Medicare model) has extremely limited pediatric application because Medicare covers children only in rare circumstances (e.g., ESRD or certain disability categories). For the vast majority of pediatric coding and risk adjustment, coders and CDI specialists should focus on HHS-HCC (commercial/exchange) and state-specific CDPS+Rx (Medicaid).
The HHS-HCC model uses age/sex factors applied differently for children (ages 0–20) than for adults. Conditions that have high adult HCC weights may carry even higher relative impact in the child model due to lower baseline per-member-per-month costs. Every accurately documented and coded qualifying condition can substantially affect plan reimbursement for pediatric members.
🗂️ Alternative Terminology
Clinicians, health plan staff, and coding professionals use varying terminology when discussing pediatric risk-adjusting conditions. The table below maps common alternative terms.
| Formal / Technical Term | Colloquial / Lay / Alternative Names |
|---|---|
| Pediatric risk adjustment | Child RAF scoring; pediatric capitation adjustment; child health status payment |
| HHS-HCC (Hierarchical Condition Category) | ACA risk adjustment HCC; exchange HCC; marketplace risk score |
| CDPS+Rx | Chronic Illness and Disability Payment System; Medicaid child risk model; CDPS Medicaid categories |
| Children with Special Health Care Needs (CSHCN) | Medically complex children; children with medical complexity (CMC); kids with special needs |
| Risk Adjustment Factor (RAF) | Risk score; HCC score; plan liability score; risk weight |
| Hierarchical Condition Category | HCC; condition category; diagnostic group |
| Condition weight / relative weight | RAF weight; cost multiplier; severity factor |
| Concurrent model | Current-year model; same-year risk model (used in most commercial/exchange RA) |
| Prospective model | Prior-year model; prior-period diagnoses; forward-looking risk scoring |
| Pediatric obesity class / severe obesity | Childhood obesity class 1, class 2, or class 3; severe obesity; BMI-for-age ≥95th percentile, ≥120% of the 95th percentile, or ≥140% of the 95th percentile, depending on class |
🩺 Signs & Symptoms
Because this guide covers a spectrum of pediatric conditions rather than a single diagnosis, signs and symptoms vary by category. The following summarizes clinical presentations that should prompt coders and CDI specialists to query for risk-adjusting diagnoses:
- Hematologic: Recurrent vaso-occlusive pain crises, acute chest syndrome, stroke/TIA in young patients (sickle cell D57.xx); prolonged bleeding, hemarthrosis, spontaneous bruising (hemophilia D66–D68).
- Pulmonary/metabolic: Chronic productive cough, failure to thrive, recurrent pulmonary infections, pancreatic insufficiency (cystic fibrosis E84.xx); persistent wheezing, nocturnal symptoms, frequent ER visits (severe persistent asthma J45.50–J45.51).
- Congenital/genetic: Characteristic dysmorphic features, hypotonia, developmental milestones delay, cardiac defects (Down syndrome Q90; Trisomy 13/18 Q91.x); murmur, cyanosis, poor feeding in newborns (major congenital heart disease).
- Neurological/neuromuscular: Hypotonia, absent deep tendon reflexes, progressive weakness (spinal muscular atrophy G12.0–G12.29); proximal muscle weakness, Gowers’ sign (muscular dystrophy G71.0); recurrent seizures (epilepsy G40.x); spastic diplegia or hemiplegia (cerebral palsy G80.x).
- Behavioral/developmental: Social communication deficits, restricted/repetitive behaviors (autism spectrum F84.0–F84.9); intellectual functioning <70 with adaptive deficits (intellectual disabilities F70–F79); inattention, hyperactivity, impulsivity with significant functional impairment and comorbidities (ADHD F90.x); speech/language regression, global developmental delay (developmental delay F88, F89).
- Endocrine/metabolic: Polyuria, polydipsia, DKA, insulin dependence from onset (type 1 diabetes E10.x); presymptomatic/early-stage type 1 diabetes documented by staging and autoantibodies (E10.A-); BMI-for-age ≥95th percentile, acanthosis nigricans (pediatric obesity Z68.54–Z68.56 with provider-documented obesity class when applicable).
- Growth/nutritional: Weight-for-age <5th percentile, faltering weight trajectory, inadequate caloric intake (failure to thrive R62.51; malnutrition E44.x); prematurity-related feeding difficulties (preterm newborn P07.xx).
- Oncologic: Lymphadenopathy, unexplained fever, pallor, bruising, bone pain (leukemia/lymphoma C00–C96).
When a child’s medical record documents recurrent hospitalizations, multiple specialists, complex medication regimens, or the use of durable medical equipment (DME), review whether underlying chronic conditions have been captured with specificity (e.g., type and severity of asthma, specific sickle cell variant, exact chromosomal disorder). These are prime indicators for concurrent risk-adjusting diagnoses that may be underreported.
🧭 Differential Diagnosis
CDI and coding professionals should consider the following differential groupings when reviewing pediatric records for risk-adjusting conditions. Not all presenting symptoms map to the highest-weighted HCC — specificity matters.
| Presenting Pattern | Conditions to Consider | Key Differentiator |
|---|---|---|
| Recurrent severe infections + anemia | Sickle cell disease (D57.0–D57.4x) vs. sickle cell trait (D57.3) vs. other hemoglobinopathies (D58.x) | Hemoglobin electrophoresis; “trait” does NOT risk-adjust the same as “disease” |
| Prolonged bleeding / hemarthrosis | Hemophilia A (D66) vs. Hemophilia B (D67) vs. von Willebrand disease (D68.0) vs. platelet disorder | Factor VIII vs. IX assay; specific factor deficiency required for HHS-HCC assignment |
| Recurrent pulmonary infections + FTT | Cystic fibrosis (E84.x) vs. primary ciliary dyskinesia (J98.09) vs. immunodeficiency (D83.x) | Sweat chloride / CFTR gene testing; CF carries highest HHS-HCC weight |
| Developmental regression + seizures | Autism spectrum disorder (F84.0–F84.9) vs. Rett syndrome (F84.2) vs. epilepsy (G40.x) vs. SMA (G12.x) | Age of onset, regression pattern, EEG, nerve conduction; multiple conditions may coexist and each codes separately |
| Hypotonia + motor delay | Spinal muscular atrophy (G12.0–G12.29) vs. muscular dystrophy (G71.0) vs. cerebral palsy (G80.x) vs. Down syndrome (Q90) | Genetic testing (SMN1/SMN2 for SMA), EMG/NCS, chromosomal microarray |
| Persistent wheezing | Severe persistent asthma (J45.50) vs. moderate persistent (J45.40) vs. reactive airway disease vs. tracheomalacia | Severity classification (NHLBI/GINA criteria); only “severe persistent” or “persistent” with controller therapy carries HHS-HCC weight |
| Elevated BMI ≥ 85th percentile | Overweight (Z68.53) vs. pediatric obesity class 1 (E66.811 + Z68.54) vs. class 2 (E66.812 + Z68.55) vs. class 3 (E66.813 + Z68.56) vs. endocrine cause (hypothyroidism E03.x, Cushing E24.x) | BMI-for-age percentile: Z68.53 = ≥85th to <95th; Z68.54 = ≥95th to <120% of the 95th percentile; Z68.55 = ≥120% to <140%; Z68.56 = ≥140%; rule out secondary causes |
| Intellectual impairment | Intellectual disability F70–F79 vs. borderline intellectual functioning (R41.83) vs. specific learning disorder (F81.x) | Standardized IQ testing + adaptive behavior; F70–F79 risk-adjusts; R41.83 generally does not |
| Insulin-dependent diabetes | Type 1 DM (E10.x) vs. Type 2 DM (E11.x) vs. MODY vs. drug-induced diabetes | Autoantibodies, C-peptide; type specificity drives HHS-HCC category assignment |
📋 Clinical Indicators
The following clinical indicators should be verified in the medical record before assigning risk-adjusting pediatric diagnoses. Documentation must support the specificity required for the ICD-10-CM code selected.
| Condition Category | Required Clinical Indicators | Documentation Source |
|---|---|---|
| Sickle cell disease | Hemoglobin electrophoresis confirming SS, SC, SB+/SB0 genotype; crisis type documented (vaso-occlusive, acute chest, sequestration) | Lab reports, hematology notes, ED/inpatient records |
| Hemophilia | Factor assay level; type (A=factor VIII, B=factor IX); inhibitor status; severity (mild/moderate/severe) | Hematology consult, lab values, infusion records |
| Cystic fibrosis | Positive sweat chloride ≥60 mmol/L or two CFTR mutations; pulmonary function staging; pancreatic involvement | Pulmonology notes, genetic reports, PFT results |
| Congenital disorders (Q-codes) | Chromosomal/genetic confirmation; severity/type of malformation; surgical history; associated anomalies | Genetics reports, echocardiograms, surgical notes |
| SMA/Muscular dystrophy | Genetic confirmation (SMN1/SMN2 copy number for SMA); EMG/NCS; functional classification; treatment (nusinersen, onasemnogene) | Neurology notes, genetic testing, therapy records |
| Autism spectrum disorder | Formal DSM-5 diagnosis; severity level (1–3); associated intellectual disability or language impairment coded separately | Behavioral/developmental pediatrician, psychiatry, neuropsychological evaluation |
| Intellectual disability | Standardized IQ <70; documented adaptive behavior deficits; severity level (mild F70, moderate F71, severe F72, profound F73) | Neuropsychological testing, school records in EHR, psychiatry notes |
| Cerebral palsy | Type (spastic, dyskinetic, ataxic); distribution (hemiplegia, diplegia, quadriplegia); associated epilepsy or intellectual disability coded separately | Neurology notes, physical/occupational therapy assessments |
| Type 1 diabetes | Autoantibody positivity or very low C-peptide; presymptomatic stage if documented (E10.A-); insulin regimen when symptomatic; HbA1c; complication status (coded separately) | Endocrinology notes, lab values, pump/CGM documentation |
| Severe persistent asthma | NHLBI/GINA severity classification documented; controller medications (high-dose ICS ± LABA/biologic); frequency of exacerbations | Pulmonology or allergy notes, medication lists, ER/inpatient visit frequency |
| Pediatric overweight/obesity | BMI-for-age percentile (CDC growth charts); age 2–20; comorbidities (sleep apnea, HTN, prediabetes); provider-documented associated diagnosis; Z68.53 for overweight and Z68.54–Z68.56 for obesity class 1–3 BMI ranges | Well-child visit notes, growth charts, anthropometric measurements |
| Cancer | Primary site, histology (pathology report); active vs. history of cancer (distinguish C vs. Z85 codes) | Oncology notes, pathology, chemotherapy/radiation records |
| Preterm/low birth weight | Gestational age at birth (weeks completed); birth weight in grams; whether condition is current vs. history; neonatal complications | Delivery records, NICU notes, neonatology documentation |
| Failure to thrive / Malnutrition | Degree of malnutrition (mild E44.1, moderate E44.0, severe E43); etiology (protein-calorie vs. specific nutrient); dietitian assessment; weight-for-age Z-score | Dietitian notes, growth charts, lab values (albumin, prealbumin) |
Coding “reactive airway disease” or “developmental delay NOS” without clarifying specificity is a common risk-adjustment gap. Reactive airway disease documented without asthma is not coded as asthma; code the symptoms, such as wheezing (AHA Coding Clinic, 3Q 2026, “Reactive Airway Disease without Asthma”). Query providers to determine whether the child meets criteria for severe persistent asthma, autism spectrum disorder, intellectual disability, or a specific neuromuscular diagnosis. Non-specific codes (e.g., F89 Unspecified developmental disorder) carry lower or no HHS-HCC weight compared to specific diagnoses.
🦴 Anatomy & Pathophysiology
This section summarizes the pathophysiology of the major pediatric risk-adjusting condition groups to help coders understand the clinical basis for documentation specificity requirements.
Hematologic Disorders
Sickle cell disease (D57.xx): An autosomal recessive hemoglobinopathy caused by a point mutation in the beta-globin gene, resulting in hemoglobin S polymerization under hypoxic conditions. This causes red blood cell sickling, vaso-occlusion, hemolytic anemia, and progressive organ damage. The most common form (HbSS) is associated with the highest morbidity. Acute chest syndrome, stroke, splenic sequestration, and pulmonary hypertension are life-threatening complications. (NHLBI Sickle Cell Disease)
Hemophilia (D66–D68): X-linked recessive deficiency of coagulation factor VIII (Hemophilia A, D66) or factor IX (Hemophilia B, D67), resulting in impaired secondary hemostasis. Characterized by spontaneous or trauma-induced hemarthroses, intramuscular bleeds, and CNS hemorrhage in severe cases. Inhibitor development (alloantibodies to replacement factor) significantly increases treatment complexity. (CDC Hemophilia)
Pulmonary/Metabolic
Cystic fibrosis (E84.xx): Autosomal recessive disorder caused by mutations in the CFTR gene encoding the cystic fibrosis transmembrane conductance regulator chloride channel. Defective chloride transport leads to viscous mucus in airways (chronic infection, bronchiectasis, respiratory failure), exocrine pancreatic insufficiency, and infertility. The F508del mutation accounts for ~70% of CF alleles. CFTR modulators (ivacaftor, elexacaftor/tezacaftor/ivacaftor) have transformed outcomes. (Cystic Fibrosis Foundation)
Severe persistent asthma (J45.50): Chronic inflammatory airway disease characterized by hyperresponsiveness and reversible airflow obstruction. Severity classification by NHLBI EPR-3 guidelines considers daytime symptoms, nighttime awakenings, SABA use, activity limitation, FEV1/FVC, and exacerbation frequency. Severe persistent requires high-dose ICS ± adjunctive therapy; biologics (dupilumab, omalizumab, mepolizumab) now indicated for pediatric severe asthma ≥6 years.
Congenital & Chromosomal Conditions
Down syndrome (Q90.x): Trisomy 21 results in characteristic facial features, hypotonia, intellectual disability, and substantially elevated risk for congenital heart defects (40–50%, most commonly AVSD), leukemia, and hypothyroidism. Associated conditions should be coded separately. (CDC Down Syndrome)
Trisomy 13 (Q91.7) / Trisomy 18 (Q91.3): Autosomal trisomies with severe multisystem anomalies including CNS malformations, cardiac defects, and high neonatal mortality. Both are high-weight HHS-HCC categories due to extreme resource utilization.
Congenital heart disease (CHD): Structural defects of the heart or great vessels present at birth. “Major CHD” includes ventricular septal defect (Q21.0), tetralogy of Fallot (Q21.3), transposition of great vessels (Q20.3), hypoplastic left heart (Q23.4), and others. Surgical complexity and ongoing need for cardiology follow-up drive high risk-adjustment weights. (See related Congenital Heart Disease CDG)
Neuromuscular & Neurological Disorders
Spinal muscular atrophy (G12.0–G12.29): Autosomal recessive disorder caused by deletions/mutations in the SMN1 gene, causing anterior horn cell degeneration and progressive muscle weakness. SMA type 1 (Werdnig-Hoffmann, G12.0) presents in infancy with severe hypotonia; without treatment, most die before age 2. Disease-modifying therapies (nusinersen, onasemnogene abeparvovec, risdiplam) have dramatically altered the natural history. (NINDS SMA)
Muscular dystrophy (G71.0): Group of inherited myopathies; Duchenne MD (DMD) is the most common severe form, caused by dystrophin gene (Xp21) deletions, affecting ~1:3,500 male births. Progressive proximal weakness, loss of ambulation by early teens, cardiomyopathy, and respiratory failure are hallmarks. Dystrophin-targeting therapies (exon-skipping) and ataluren are in use. (CDC Muscular Dystrophy)
Cerebral palsy (G80.x): Non-progressive disorder of movement and posture resulting from damage to the developing brain. Types include spastic (most common, G80.0–G80.2), dyskinetic (G80.3), ataxic (G80.4). Associated conditions — epilepsy, intellectual disability, autism — frequently co-exist and each should be coded separately as they independently risk-adjust.
Epilepsy (G40.x): Recurrent unprovoked seizures. Code specificity requires seizure type (focal vs. generalized), intractability, and status epilepticus. Intractable epilepsy carries higher HHS-HCC weight. See the related Epilepsy CDG for full coding guidance.
Behavioral & Developmental Conditions
Autism spectrum disorder (F84.0–F84.9): Neurodevelopmental condition characterized by deficits in social communication/interaction and restricted, repetitive behaviors. DSM-5 consolidates all subtypes under ASD with three severity levels (requiring support, requiring substantial support, requiring very substantial support). Prevalence is ~1 in 36 children per CDC ADDM 2023 data. ASD maps to HHS-HCC in commercial/exchange models.
Intellectual disabilities (F70–F79): Significant limitations in intellectual functioning (IQ typically <70) and adaptive behavior, originating before age 18. Severity levels (mild, moderate, severe, profound) must be specified. The etiology should also be coded when known (e.g., Down syndrome, fragile X syndrome Q99.2).
Endocrine & Nutritional
Type 1 diabetes mellitus (E10.x): Autoimmune destruction of pancreatic beta cells, resulting in absolute insulin deficiency. Children present with DKA and require lifelong insulin therapy. Code complications when present (nephropathy, retinopathy, neuropathy, hypoglycemia) as they carry additional HHS-HCC weight. (ADA Standards of Care 2022)
Pediatric obesity (E66.811–E66.813 with Z68.54–Z68.56): For ages 2–20, pediatric BMI codes use CDC age- and sex-specific BMI-for-age thresholds, not adult BMI-only cutoffs. Z68.54 represents BMI ≥95th percentile to <120% of the 95th percentile, Z68.55 represents ≥120% to <140%, and Z68.56 represents ≥140%; obesity class codes E66.811–E66.813 may be assigned when the provider documents the class.
💊 Medication Impact / Treatment
Medications used to treat pediatric risk-adjusting conditions both confirm the diagnosis and — in some models — directly trigger risk category assignment in CDPS+Rx (which includes pharmacy data). Key medication classes and their coding implications:
| Condition | Key Medications / Therapies | Coding/RA Implication |
|---|---|---|
| Sickle cell disease | Hydroxyurea, crizanlizumab (Adakveo), L-glutamine; chronic transfusion therapy; hematopoietic stem cell transplant; gene therapy for eligible patients | Presence of disease-modifying therapy or transfusion therapy corroborates SCD diagnosis; code causal condition, not just anemia |
| Hemophilia | Factor VIII/IX concentrates (recombinant or plasma-derived); emicizumab (Hemlibra); desmopressin for mild hemophilia A | Infusion records support hemophilia coding; inhibitor status (D66 vs. D68.311) changes code and risk weight |
| Cystic fibrosis | CFTR modulators (ivacaftor/Kalydeco, elexacaftor/tezacaftor/ivacaftor/Trikafta); inhaled antibiotics (tobramycin, aztreonam); dornase alfa; pancreatic enzymes | CFTR modulator use confirms genotype; code both E84.0 (with pulmonary manifestations) and E84.19 (with other GI) when both present |
| SMA | Nusinersen (Spinraza), onasemnogene abeparvovec-xioi (Zolgensma), risdiplam (Evrysdi) | Gene therapy and high-cost biologics confirm SMA diagnosis; code SMA type specifically (G12.0 type 1; G12.1 types 2, 3 [Kugelberg-Welander], and adult forms) |
| Muscular dystrophy | Corticosteroids (deflazacort, prednisone); exon-skipping agents (eteplirsen, golodirsen, casimersen, viltolarsen); ataluren | Steroid-associated complications (adrenal insufficiency, growth impairment) should be coded as additional diagnoses |
| Severe persistent asthma | High-dose ICS (fluticasone ≥500 mcg/day), ICS/LABA; biologics (omalizumab/Xolair ≥6 yr, mepolizumab/Nucala ≥6 yr, dupilumab/Dupixent ≥6 yr) | Biologic therapy is indicator of severe persistent asthma (J45.50); “moderate persistent” (J45.40) does not trigger same HHS-HCC category |
| Type 1 DM | Insulin (basal-bolus regimens); insulin pump (CSII); continuous glucose monitoring (CGM); glucagon emergency kit | Insulin pump use supports Z96.41 when documented; Z79.4 identifies long-term insulin use when applicable. CGM use supports active diabetes management, but Z79.85 is for injectable non-insulin antidiabetic drugs, not CGM; code E10.- complication/status specificity |
| Autism / Behavioral | Aripiprazole (Abilify), risperidone (irritability/ASD); SSRIs; stimulants for comorbid ADHD; applied behavior analysis (ABA) therapy | Antipsychotic use in children should prompt review of underlying behavioral diagnosis for RA capture; ABA billing supports ASD coding |
| Epilepsy | Levetiracetam, valproate, lamotrigine, oxcarbazepine, clobazam; ketogenic diet; vagus nerve stimulator; responsive neurostimulation | Drug-resistant/intractable epilepsy (G40.x11 or x19) carries higher weight; document intractability explicitly |
| Pediatric obesity | Metformin (off-label); phentermine/topiramate (≥12 yr); semaglutide (Wegovy ≥12 yr); orlistat; bariatric surgery (rare ≥13 yr) | GLP-1 agonist or bariatric surgery documents severity; code Z68.53 or Z68.54 based on specific BMI value |
When a child’s medication list includes high-cost specialty biologics (e.g., Spinraza, Zolgensma, Trikafta, Hemlibra, Dupixent), this is a strong signal that a high-weight risk-adjusting diagnosis should be present in the record. If the corresponding specific diagnosis code is absent or non-specific, initiate a CDI query to the prescribing provider to confirm and document the underlying condition with the required specificity.
Preview ends here. The full guide continues with FY2027 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 ICD-10-CM Guidelines
The following guidelines from the FY2027 ICD-10-CM Official Guidelines for Coding and Reporting are critical for pediatric risk-adjusting conditions.
Section I.C. — Chapter-Specific Guidelines
- Sickle cell disease (Chapter 3 — D50–D89): Code the type of crisis when present (e.g., D57.00 Hb-SS disease with crisis, unspecified; D57.01 Hb-SS disease with acute chest syndrome). “Sickle-cell trait” (D57.3) is NOT a disease — do not assign disease codes for trait carriers without clinical manifestation.
- Diabetes mellitus (Chapter 4 — E08–E13): Type 1 DM (E10.x) should be coded with the appropriate characters to identify complications; FY2027 guidelines also recognize E10.A- for presymptomatic/early-stage type 1 diabetes. When a patient uses an insulin pump, assign Z96.41 (presence of insulin pump) as an additional code when applicable.
- Cystic fibrosis (Chapter 4): E84.0 (CF with pulmonary manifestations) and E84.19 (CF with other GI manifestations) may be assigned together. Assign the manifestation codes additionally when documented (e.g., bronchiectasis J47.x, malabsorption K90.3).
- Congenital malformations (Chapter 17 — Q00–Q99): Q-code conditions are always reportable, even in adults, when they continue to affect patient management. Do not assume they are “historical” once the patient is discharged from NICU.
- Autism spectrum (Chapter 5 — F01–F99): Per DSM-5 alignment, code F84.0 (Autistic disorder) for ASD Level 1–3. When intellectual disability co-exists, assign a code from F70–F79 additionally. Language impairment (F80.x) and associated conditions should each be coded separately.
- Intellectual disability (Chapter 5): Assign the severity code (F70–F73, F78, F79). When caused by a known condition (e.g., Down syndrome), code the underlying condition first if it is the focus of the encounter.
- Malnutrition (Chapter 4): Malnutrition codes (E40–E46) should be assigned based on documented dietitian or physician assessment using validated tools. Coders should NOT assume or assign malnutrition from BMI/weight data alone without physician documentation.
- Perinatal conditions (Chapter 16 — P00–P96): P07.xx codes (disorders related to short gestation and low birth weight) are used only during the perinatal period or when the condition directly affects current management in later encounters. After the perinatal period, use Z87.68 (personal history of other [corrected] conditions arising in the perinatal period) when only history is documented and the historical condition affects care.
- Cancer (Chapter 2 — C00–D49): Active malignancy codes (C00–C96) are assigned when treatment is active. Once treatment is complete and no evidence of disease remains, assign Z85.x (history of cancer). Do NOT code “history of” with an active treatment code simultaneously.
- BMI in children (Chapter 21 — Z68.x): Z68.5x codes are for pediatric patients ages 2–20, using BMI-for-age percentile from CDC growth charts. Z68.53 = BMI ≥85th to <95th percentile; Z68.54 = BMI ≥95th percentile to <120% of the 95th percentile; Z68.55 = BMI ≥120% to <140% of the 95th percentile; Z68.56 = BMI ≥140% of the 95th percentile. Assign BMI codes only with a provider-documented associated, reportable diagnosis such as overweight or obesity; when provider documentation supports an obesity class, use E66.811–E66.813 as appropriate and report the BMI code as an additional code.
For ACA exchange risk adjustment, all qualifying diagnoses must appear in a face-to-face encounter with an in-network provider during the data collection year. Diagnoses recorded only in lab reports, telephone encounters, or portal messages without a corresponding in-person (or qualifying telehealth) visit will NOT count toward risk score. Confirm that each risk-adjusting pediatric diagnosis is tied to a documented clinical encounter in the plan year.
Additional Coding Guidance
- Cerebral palsy: Assign G80.x based on type and distribution. G80.0 (spastic quadriplegic), G80.1 (spastic diplegic), G80.2 (spastic hemiplegic), G80.3 (athetoid), G80.4 (ataxic). Associated epilepsy (G40.x) and intellectual disability (F70–F79) are coded additionally.
- ADHD with comorbidities (F90.x): ADHD alone does not consistently trigger HHS-HCC assignment. When documented with significant psychiatric comorbidities (e.g., bipolar disorder F31.x, schizophrenia F20.x, conduct disorder F91.x), the comorbid condition drives the RA value. Code all documented diagnoses.
- Developmental delay: F88 (Other disorders of psychological development) and F89 (Unspecified disorder of psychological development) are low-specificity codes. Query the provider to determine whether criteria for ASD (F84.0), intellectual disability (F70–F79), or specific developmental disorder (F80–F81) are met before assigning F88/F89.
- Well-child visits: Z00.121 (encounter for routine child health examination with abnormal findings) triggers obligation to code the abnormal finding. Z00.129 (without abnormal findings) should be used when the child is fully healthy. If a chronic condition is monitored at the well-child visit, it should still be coded as an additional diagnosis.
🔢 ICD-10-CM Code Set (Tabular)
The following table presents the primary FY2027 ICD-10-CM codes for pediatric risk-adjusting conditions. All codes verified against the FY2027 ICD-10-CM tabular list.
| ICD-10-CM Code | Description | HHS-HCC V08 (BY 2026, DIY Table 3) | Notes |
|---|---|---|---|
| D57.00 | Hb-SS disease with crisis, unspecified | HHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero | Use when Hb-SS crisis is documented but the crisis type is not specified; code crisis type when known |
| D57.01 | Hb-SS disease with acute chest syndrome | HHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero | Life-threatening complication; distinct code |
| D57.02 | Hb-SS disease with splenic sequestration | HHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero | Code separately when documented |
| D57.1 | Sickle-cell disease without crisis, Hb-SS disease | HHS-HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero | Use when in stable phase; D57.3 (trait) does NOT map to this HCC |
| D57.20 | Sickle-cell/Hb-C disease without crisis | HHS-HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia Major | HbSC — less severe but still RA |
| D57.40 | Sickle-cell thalassemia, unspecified, without crisis | HHS-HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta Zero; Beta Thalassemia Major | Code specific variant (SB+/SB0) when documented |
| D66 | Hereditary factor VIII deficiency (Hemophilia A) | HHS-HCC 66 — Hemophilia (male); HHS-HCC 75 — Coagulation Defects and Other Specified Hematological Disorders (female) | Classical hemophilia; HHS-HCC 66 for males, 75 for females; add D68.311 if inhibitor present |
| D67 | Hereditary factor IX deficiency (Hemophilia B) | HHS-HCC 66 — Hemophilia (male); HHS-HCC 75 — Coagulation Defects and Other Specified Hematological Disorders (female) | Christmas disease |
| D68.00–D68.09 | Von Willebrand disease | HHS-HCC 75 — Coagulation Defects and Other Specified Hematological Disorders | Use the most specific billable code: D68.00 unspecified, D68.01 type 1, D68.020–D68.029 type 2 subtypes, D68.03 type 3, D68.04 acquired, D68.09 other |
| E84.0 | Cystic fibrosis with pulmonary manifestations | HHS-HCC 159 — Cystic Fibrosis | Also maps to CMS-HCC V28 HCC 277 (Cystic Fibrosis) |
| E84.11 | Meconium ileus in cystic fibrosis | HHS-HCC 159 — Cystic Fibrosis | Neonatal presentation |
| E84.19 | Cystic fibrosis with other intestinal manifestations | HHS-HCC 159 — Cystic Fibrosis | Code with E84.0 when both present |
| E84.8 | Cystic fibrosis with other manifestations | HHS-HCC 159 — Cystic Fibrosis | Includes other CF manifestations; for diabetes due to cystic fibrosis, code E84.- first with E08.- for diabetes mellitus due to underlying condition, using complication specificity |
| E84.9 | Cystic fibrosis, unspecified | HHS-HCC 159 — Cystic Fibrosis | Avoid — use specific manifestation codes |
| Q90.0 | Trisomy 21, meiotic nondisjunction | HHS-HCC 97 — Down Syndrome, Fragile X, Other Chromosomal Anomalies, and Congenital Malformation Syndromes | Down syndrome — most common chromosomal disorder |
| Q90.9 | Down syndrome, unspecified | HHS-HCC 97 — Down Syndrome, Fragile X, Other Chromosomal Anomalies, and Congenital Malformation Syndromes | Use Q90.0-Q90.2 when cytogenetic type known |
| Q91.3 | Trisomy 18, unspecified | HHS-HCC 96 — Prader-Willi, Patau, Edwards, and Autosomal Deletion Syndromes | Edwards syndrome |
| Q91.7 | Trisomy 13, unspecified | HHS-HCC 96 — Prader-Willi, Patau, Edwards, and Autosomal Deletion Syndromes | Patau syndrome |
| Q35.1 | Cleft hard palate | HHS-HCC 63 — Cleft Lip/Cleft Palate | See Cleft Lip/Palate CDG |
| Q37.0 | Cleft hard palate with bilateral cleft lip | HHS-HCC 63 — Cleft Lip/Cleft Palate | Multiple surgical procedures; high resource utilization |
| Q00.0 | Anencephaly | HHS-HCC 114 — Spina Bifida and Other Brain/Spinal/Nervous System Congenital Anomalies | See neural tube defect coding guidance |
| Q05.0–Q05.9 | Spina bifida | HHS-HCC 114 — Spina Bifida and Other Brain/Spinal/Nervous System Congenital Anomalies; HHS-HCC 121 — Hydrocephalus | Code level and whether with or without hydrocephalus |
| Q21.3 | Tetralogy of Fallot | HHS-HCC 138 — Major Congenital Heart/Circulatory Disorders | See CHD CDG |
| Q20.3 | Discordant ventriculoarterial connection (TGA) | HHS-HCC 138 — Major Congenital Heart/Circulatory Disorders | Transposition of the great arteries |
| Q23.4 | Hypoplastic left heart syndrome | HHS-HCC 137 — Hypoplastic Left Heart Syndrome and Other Severe Congenital Heart Disorders | Requires staged surgical palliation (Norwood, Glenn, Fontan) |
| G12.0 | Infantile spinal muscular atrophy, type I (Werdnig-Hoffmann) | HHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell Disease | Most severe SMA; gene therapy indicated |
| G12.1 | Other inherited spinal muscular atrophy (type II, III) | HHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell Disease | G12.1 includes SMA type II, type III (Kugelberg-Welander), and adult forms; G12.21 is ALS, not SMA |
| G12.29 | Other motor neuron disease | HHS-HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell Disease | Rare SMA variants; verify provider documentation of type |
| G71.00 | Muscular dystrophy, unspecified | HHS-HCC 117 — Muscular Dystrophy | Avoid; use specific type below |
| G71.01 | Duchenne or Becker muscular dystrophy | HHS-HCC 117 — Muscular Dystrophy | Use for Duchenne or Becker muscular dystrophy; most common severe dystrophinopathy group in children |
| G71.02 | Facioscapulohumeral muscular dystrophy | HHS-HCC 117 — Muscular Dystrophy | Use for facioscapulohumeral muscular dystrophy; Becker muscular dystrophy is included in G71.01 |
| G80.0 | Spastic quadriplegic cerebral palsy | HHS-HCC 112 — Quadriplegic Cerebral Palsy | Most severe CP type; code associated epilepsy, ID separately |
| G80.1 | Spastic diplegic cerebral palsy | HHS-HCC 113 — Cerebral Palsy, Except Quadriplegic | Predominantly lower extremity |
| G80.2 | Spastic hemiplegic cerebral palsy | HHS-HCC 113 — Cerebral Palsy, Except Quadriplegic | Unilateral involvement |
| G80.3 | Athetoid cerebral palsy | HHS-HCC 113 — Cerebral Palsy, Except Quadriplegic | Dyskinetic; often due to kernicterus or HIE |
| G80.4 | Ataxic cerebral palsy | HHS-HCC 113 — Cerebral Palsy, Except Quadriplegic | Cerebellar dysfunction predominant |
| G40.301 | Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus | HHS-HCC 120 — Seizure Disorders and Convulsions | See Epilepsy CDG; intractable = higher weight |
| G40.311 | Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus | HHS-HCC 120 — Seizure Disorders and Convulsions | “Intractable” = drug-resistant; document explicitly |
| F84.0 | Autistic disorder (Autism Spectrum Disorder) | HHS-HCC 102 — Autistic Disorder | DSM-5 ASD; code severity level via associated specifiers; comorbid ID coded separately |
| F84.5 | Asperger syndrome | HHS-HCC 103 — Pervasive Developmental Disorders, Except Autistic Disorder | DSM-5 subsumed under ASD; may still be documented in older records |
| F70 | Mild intellectual disability | No HHS-HCC | IQ 50–69; code etiology when known |
| F71 | Moderate intellectual disability | No HHS-HCC | IQ 35–49 |
| F72 | Severe intellectual disability | No HHS-HCC | IQ 20–34 |
| F73 | Profound intellectual disability | No HHS-HCC | IQ <20 |
| F20.9 | Schizophrenia, unspecified | HHS-HCC 87_1 — Schizophrenia (age >= 2) | Early-onset schizophrenia (<18) is rare; document age of onset |
| F31.0–F31.9 | Bipolar disorder | HHS-HCC 88 — Major Depressive Disorder, Severe, and Bipolar Disorders (age >= 2) | Specify current episode type and severity |
| E10.9 | Type 1 diabetes mellitus without complications | HHS-HCC 21 — Diabetes without Complication; HHS-HCC 22 — Type 1 Diabetes Mellitus, add-on to Diabetes HCCs 19-21 (age >= 21) | Use when type 1 diabetes is documented without complications; E10.10 is type 1 diabetes mellitus with ketoacidosis without coma |
| E10.641 | Type 1 DM with hypoglycemia with coma | HHS-HCC 19 — Diabetes with Acute Complications; HHS-HCC 22 — Type 1 Diabetes Mellitus, add-on to Diabetes HCCs 19-21 (age >= 21) | Higher-weight subcategory |
| J45.50 | Severe persistent asthma, uncomplicated | HHS-HCC 161_1 — Severe Asthma | NHLBI step 5–6; biologic use confirms severity |
| J45.51 | Severe persistent asthma with (acute) exacerbation | HHS-HCC 161_1 — Severe Asthma | Code exacerbation status |
| C91.00 | Acute lymphoblastic leukemia not achieved remission | HHS-HCC 8 — Metastatic Cancer (age >= 18); HHS-HCC 9 — Lung, Brain, and Other Severe Cancers, Including Pediatric Acute Lymphoid Leukemia (age < 18) | ALL is most common pediatric cancer |
| C91.01 | Acute lymphoblastic leukemia, in remission | HHS-HCC 8 — Metastatic Cancer (age >= 18); HHS-HCC 9 — Lung, Brain, and Other Severe Cancers, Including Pediatric Acute Lymphoid Leukemia (age < 18) | Still codes as active cancer during treatment |
| C00–C96 | Malignant neoplasms (all types) | HHS-HCC 8–13 by site and type (cancer) | Code primary site + histology; active treatment vs. history |
| P07.00 | Extremely low birth weight newborn, weight not specified | HHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0) | Newborn HHS-HCCs apply only at age 0 (infant model); no CMS-HCC V28 HCC |
| P07.10 | Other low birth weight newborn, weight not specified | HHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0) | 1000–2499g range |
| P07.30 | Preterm newborn, unspecified weeks of gestation | HHS-HCC 248 — Other Premature, Low Birthweight, Malnourished, or Multiple Birth Newborns (age = 0) | Use specific week codes (P07.31–P07.39) when documented |
| R62.51 | Failure to thrive (child) | No HHS-HCC | See related CDG; query for underlying malnutrition diagnosis |
| E44.0 | Moderate protein-calorie malnutrition | HHS-HCC 23 — Protein-Calorie Malnutrition | Requires dietitian or physician documentation of degree |
| E44.1 | Mild protein-calorie malnutrition | HHS-HCC 23 — Protein-Calorie Malnutrition | Lower weight than E43/E44.0 |
| E43 | Unspecified severe protein-calorie malnutrition | HHS-HCC 23 — Protein-Calorie Malnutrition | Code when the provider documents severe protein-calorie malnutrition; nutritional marasmus is E41 and marasmic kwashiorkor is E42 |
| E66.811–E66.813 | Obesity class 1, class 2, or class 3 | No HHS-HCC | Use provider-documented obesity class; report Z68.54–Z68.56 as additional pediatric BMI codes when documented |
| Z68.53 | BMI pediatric ≥85th-<95th percentile for age | No HHS-HCC | Overweight only; does NOT trigger morbid obesity HCC |
| Z68.54–Z68.56 | BMI pediatric obesity range | No HHS-HCC | Z68.54 = ≥95th percentile to <120% of the 95th percentile; Z68.55 = ≥120% to <140%; Z68.56 = ≥140%; report only as an additional code with a provider-documented associated diagnosis |
| F90.0 | ADHD, predominantly inattentive type | No HHS-HCC | ADHD alone = limited RA; code comorbidities fully |
| F90.1 | ADHD, predominantly hyperactive type | No HHS-HCC | Specify type per provider documentation |
| F90.2 | ADHD, combined type | No HHS-HCC | Most common ADHD presentation in children |
| F88 | Other disorders of psychological development | No HHS-HCC | Query for ASD, ID, or specific developmental disorder |
| F89 | Unspecified disorder of psychological development | No HHS-HCC | Avoid; query for specific diagnosis |
| Z00.121 | Encounter for routine child health exam with abnormal findings | No HHS-HCC | Must code the abnormal finding(s) additionally |
| Z00.129 | Encounter for routine child health exam without abnormal findings | No HHS-HCC | Do NOT use when chronic conditions are monitored |
Under the HHS-HCC concurrent risk adjustment model, ALL qualifying diagnoses reported during the benefit year (not just principal diagnoses) contribute to the risk score. This means coders should capture every active, chronic, clinically significant pediatric condition at every encounter — including preventive visits — as long as it is documented and clinically supported. Risk adjustment is not limited to inpatient claims.
🔎 Indexing
The following ICD-10-CM Alphabetic Index pathways guide coders to the correct codes for major pediatric risk-adjusting conditions. All index references are per the FY2027 ICD-10-CM Official Index.
- Sickle cell: Disease, sickle-cell → Hb-SS → see D57.0x (with crisis subterms) or D57.1 (without crisis)
- Hemophilia A: Hemophilia → A (classical) → D66; with inhibitor → see D68.311
- Cystic fibrosis: Fibrosis, cystic → see E84; with pulmonary manifestations → E84.0; with meconium ileus → E84.11
- Down syndrome: Syndrome, Down → see Q90; trisomy, 21 → Q90.0 (meiotic nondisjunction)
- SMA: Atrophy, muscle, spinal → progressive; infantile (Werdnig-Hoffmann) → G12.0; Kugelberg-Welander → G12.1
- Muscular dystrophy: Dystrophy, muscular → Duchenne or Becker → G71.01; facioscapulohumeral → G71.02
- Cerebral palsy: Palsy, cerebral → spastic; quadriplegic → G80.0; diplegic → G80.1; hemiplegic → G80.2
- Autism: Disorder, autistic → F84.0; Asperger → F84.5
- Intellectual disability: Disability, intellectual → mild → F70; moderate → F71; severe → F72; profound → F73
- Asthma: Asthma → severe persistent → uncomplicated → J45.50; with exacerbation → J45.51; with status asthmaticus → J45.52
- Type 1 DM: Diabetes, type 1 → E10; with complication → see specific 4th/5th character subterms
- Obesity (pediatric): Obesity → class 1/class 2/class 3 → E66.811–E66.813 when provider-documented; BMI → pediatric → overweight/obesity percentile ranges → Z68.53–Z68.56
- Failure to thrive: Failure, thrive (child) → R62.51; Malnutrition → moderate protein-calorie → E44.0
- Preterm newborn: Newborn, premature → see also P07.3x; low birth weight → P07.0x–P07.1x
- Epilepsy: Epilepsy → generalized → idiopathic → not intractable → G40.309; intractable → G40.319
🏥 CPT
The following CPT codes are used for pediatric evaluation, management, developmental screening, and procedures related to risk-adjusting conditions. All codes verified per AMA CPT 2027.
| CPT Code | Description | Global Period | Notes / Risk Adjustment Tie-in |
|---|---|---|---|
| 99381 | New patient preventive E&M, infant (<1 year) | N/A | Well-child visit; code chronic conditions additionally if present and monitored |
| 99382 | New patient preventive E&M, early childhood (1–4 years) | N/A | Developmental screening expected at 9, 18, 24/30 months per AAP |
| 99383 | New patient preventive E&M, late childhood (5–11 years) | N/A | Capture any newly identified chronic diagnoses (asthma, ASD, epilepsy) |
| 99384 | New patient preventive E&M, adolescent (12–17 years) | N/A | Screen for behavioral health; capture F-code diagnoses for RA |
| 99391 | Established patient preventive E&M, infant (<1 year) | N/A | Use Z00.121 if chronic condition managed; triggers RA diagnosis capture |
| 99392 | Established patient preventive E&M, early childhood (1–4 years) | N/A | ASD screening per AAP at 18 and 24 months; M-CHAT-R/F results documented |
| 99393 | Established patient preventive E&M, late childhood (5–11 years) | N/A | Chronic disease management review; confirm all active diagnoses captured |
| 99394 | Established patient preventive E&M, adolescent (12–17 years) | N/A | Obesity BMI percentile documented; Z68.54 + E66.01 when applicable |
| 99395 | Established patient preventive E&M, 18–39 years | N/A | Applies to young adults 18+ in pediatric/transition practice |
| 96110 | Developmental screening (e.g., Developmental Milestones Inventory, Parents’ Evaluation of Developmental Status [PEDS]), with interpretation and report | N/A | Supports developmental delay / ASD documentation; M-CHAT autism screening billed here |
| 96127 | Brief emotional/behavioral assessment (e.g., PHQ-9 pediatric, Vanderbilt ADHD) | N/A | Supports ADHD, behavioral health diagnoses; documents severity for RA |
| 96130 | Psychological testing evaluation by physician/QHP, first hour | N/A | Formal psychological testing; supports intellectual disability coding (F70–F73) |
| 96131 | Psychological testing evaluation, each additional hour | N/A | Append to 96130 for extended testing sessions |
| 99213–99215 | Office/outpatient E&M, established patient, varying complexity | N/A | For problem-focused visits managing risk-adjusting diagnoses; captures RA codes |
| 27422 | Reconstruction of quadriceps mechanism (e.g., for CP spasticity) | 90 days | Surgical codes for CP complications; supports G80.x coding |
| 64642–64645 | Chemodenervation of extremity muscle(s); 1–4 or 5 or more muscles, including additional extremity add-on codes | N/A | Supports G80.x diagnosis documentation when botulinum toxin is used for CP-related limb spasticity |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies; complete | N/A | Documents CHD; confirms Q20–Q23 coding for major CHD HHS-HCC |
| 33470 | Valvotomy, pulmonary valve, closed heart; via catheter | 90 days | Surgical procedure for CHD; supports Q22.1 coding |
| 94010 | Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s) | N/A | PFT supports asthma severity classification (J45.50 vs J45.40) |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | N/A | Acute asthma exacerbation treatment (J45.51) |
| 90791 | Psychiatric diagnostic evaluation | N/A | Formal psychiatric assessment; supports F20.x, F31.x, F84.0 coding |
| 90837 | Psychotherapy, 60 minutes | N/A | Ongoing behavioral health treatment; documents active psychiatric diagnoses |
| 36430 | Transfusion, blood or blood components | N/A | For sickle cell/hemophilia transfusions; supports D57.x, D66–D68 coding |
Well-child visits (99381–99395) are a critical opportunity for risk adjustment diagnosis capture. Under ACA exchange RA rules, diagnoses reported on any claim type — including preventive visits — count toward the plan year risk score. Ensure that all active, chronic, clinically significant diagnoses are listed on the claim for every encounter, including wellness visits, not just problem-focused visits.
🧾 HCPCS
HCPCS Level II codes used in pediatric risk-adjusting condition management. Codes verified against CMS HCPCS 2026 quarterly release.
| HCPCS Code | Description | Typical Pediatric Use |
|---|---|---|
| G0444 | Annual depression screening, 15 minutes | Adolescent depression screening (PHQ-A); supports F31.x, F32.x diagnosis capture |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | Developmental assessment supporting ASD (F84.0), ID (F70–F73), developmental delay (F88) coding |
| H0031 | Mental health assessment, by non-physician | Behavioral health evaluation for ASD, ADHD, bipolar, schizophrenia spectrum in children |
| H0032 | Mental health service plan development by non-physician | Care planning for F84.0, F90.x, F31.x diagnoses |
| H0034 | Medication training and support, per 15 minutes | Psychotropic medication management in pediatric behavioral health |
| H0036 | Community psychiatric supportive treatment, face-to-face, per 15 minutes | Intensive community-based services for severely mentally ill children (F20.x, F31.x) |
| H0038 | Self-help/peer services, per 15 minutes | Peer support for adolescents with serious mental illness |
| H2012 | Behavioral health day treatment, per hour | Partial hospitalization / day programs for severe pediatric psychiatric diagnoses |
| H2014 | Skills training and development, per 15 minutes | Applied behavior analysis (ABA) and social skills training for ASD; supports F84.0 |
| H2019 | Therapeutic behavioral services, per 15 minutes | Intensive behavioral support for ASD, ID, challenging behavior |
| S5108 | Home care training to home care client, per 15 minutes | Training for caregivers of children with complex medical needs (SMA, CF, CP) |
| T1017 | Targeted case management, each 15 minutes | Care coordination for CSHCN; supports documentation of multiple risk-adjusting diagnoses |
| J7310 | Ganciclovir, 4.5 mg, implant | Not pediatric-specific; included for completeness |
| J2350 | Injection, ocrelizumab, 1 mg (Ocrevus) | Rare pediatric MS; included for neuromuscular completeness |
| J0179 | Injection, brolucizumab-dbll, 1 mg (Beovu) | Retinal disease; included for completeness |
| J0517 | Injection, benralizumab, 1 mg (Fasenra) | Biologic for severe persistent asthma ≥12 yr; J45.50 diagnosis required |
| J0222 | Injection, patisiran, 0.5 mg (Onpattro) | Rare hereditary TTR polyneuropathy; neuromuscular category |
| Q4100 | Skin substitute, not otherwise specified | Wound care for EB (epidermolysis bullosa Q81.x) — congenital skin fragility, RA-qualifying |
📚 AHA Coding Clinic
Verified Coding Clinic, guideline, and Tabular sources for pediatric risk-adjusting conditions:
- Sickle-cell disease (FY 2027 ICD-10-CM Tabular List; Coding Clinic, Fourth Quarter 2020; Coding Clinic, Fourth Quarter 2023): D57.1 (Sickle-cell disease without crisis) is the default for sickle-cell disease NOS. Crisis codes are type-specific, including acute chest syndrome, splenic sequestration, cerebral vascular involvement (FY 2021), and dactylitis (FY 2024). Coding Clinic, Fourth Quarter 2023, assigns D57.04 (Hb-SS disease with dactylitis) plus R50.81 for an infant with SCD, dactylitis, and fever.
- Malnutrition (FY 2027 ICD-10-CM Official Guidelines, Section I.B.14; Coding Clinic, Third Quarter 2017): A dietitian may document the BMI, but “the associated diagnosis … must be documented by the patient’s provider.” “Severe malnutrition” indexes to E43; do not assign E40 or E42 unless kwashiorkor is specifically documented.
- Cystic fibrosis manifestations (Coding Clinic, First Quarter 2021; FY 2027 ICD-10-CM Tabular List, E08): For a CF exacerbation with bronchiectasis, assign E84.0 as principal and J47.1 for the manifestation. For CF-related diabetes, the E08 note says “code first the underlying condition, such as cystic fibrosis (E84.-),” then the E08.- code.
- Perinatal conditions after the newborn period (FY 2027 ICD-10-CM Official Guidelines, Section I.C.16.a.4; Coding Clinic, Third Quarter 2017): “Should a condition originate in the perinatal period, and continue throughout the life of the patient, the perinatal code should continue to be used regardless of the patient’s age.” Use Z87.68 only when the perinatal condition has resolved. ICD-10-CM does not classify infants of 37 weeks or more as preterm; do not code “late preterm infant” at 37 weeks.
- Pediatric BMI (FY 2027 ICD-10-CM Tabular List, Z68): Pediatric BMI codes Z68.51–Z68.56 are for patients 2–19 years of age and use CDC growth-chart percentiles. Assign them only with an associated reportable diagnosis (for example, obesity) documented by the provider.
Source note: Coding Clinic items below were read in full on Find-A-Code (AHA Coding Clinic for ICD-10-CM and ICD-10-PCS). Items without a Coding Clinic issue rest on the FY 2027 Official Guidelines or Tabular List, as labeled. Codes valid as of the FY 2027 ICD-10-CM code set; HCCs per the 2024 CMS-HCC model (V28), 2027 Initial mappings.
💰 HCC / Risk Adjustment
The HHS-HCC model is the main risk adjustment model for children (child model ages 2–20; infant model ages 0–1). CMS-HCC V28 applies to Medicare beneficiaries, so it rarely applies to children; it is shown for comparison. This guide shows two models side by side. CMS-HCC V28 (the 2024 CMS-HCC model, continued for CY 2027) is used for Medicare Advantage; mappings follow the CMS 2027 Initial ICD-10-CM Mappings. HHS-HCC V08 is used for ACA individual and small-group plans; mappings follow the 2026 benefit year HHS-HCC DIY Table 3 (July 31, 2026), which covers FY 2026 codes and will be revised for FY 2027 codes. The two models use different HCC numbers; never mix them. RAF weights vary by segment and metal level and are not quoted here. Code every documented condition; CMS applies the hierarchies.
| ICD-10-CM Code(s) | Description | CMS-HCC V28 (Medicare Advantage) | HHS-HCC V08 (ACA, BY 2026) | Coding / Documentation Notes |
|---|---|---|---|---|
| E84.0–E84.9 | Cystic fibrosis | HCC 277 — Cystic Fibrosis | HCC 159 — Cystic Fibrosis | — |
| D57.00–D57.1 | Sickle cell disease Hb-SS, with or without crisis | HCC 107 | HCC 70 — Sickle Cell Anemia (Hb-SS) and Thalassemia Beta Zero | Infant models assign HCC 70 and 71 a higher severity |
| D57.20–D57.819 | Hb-SC disease, sickle-cell thalassemia, other sickle-cell disorders | HCC 108 | HCC 71 — Sickle-Cell Disorders, Except Sickle-Cell Anemia (Hb-SS) and Thalassemia Beta Zero | D57.3 (trait) maps in neither |
| D66, D67 | Hemophilia A and B | HCC 111 (female: 112) | HCC 66 — Hemophilia (male); HCC 75 (female) | Sex split in both models |
| G12.0, G12.1 | Infantile and other inherited spinal muscular atrophy | HCC 190 | HCC 111 — Amyotrophic Lateral Sclerosis and Other Anterior Horn Cell Disease | — |
| G71.00–G71.09 | Muscular dystrophy | HCC 197 | HCC 117 — Muscular Dystrophy | — |
| G80.0; G80.1–G80.9 | Spastic quadriplegic cerebral palsy; other cerebral palsy | HCC 191; HCC 192 | HCC 112 — Quadriplegic Cerebral Palsy; HCC 113 — Cerebral Palsy, Except Quadriplegic | — |
| G40.- | Epilepsy | HCC 201 | HCC 120 — Seizure Disorders and Convulsions | — |
| F84.0; F84.5, F84.9 | Autistic disorder; Asperger syndrome, pervasive developmental disorder unspecified | No V28 payment HCC | HCC 102 — Autistic Disorder; HCC 103 — Pervasive Developmental Disorders, Except Autistic Disorder | — |
| F90.-, F70–F79 | ADHD; intellectual disabilities | No V28 payment HCC | No HHS-HCC | — |
| E10.- | Type 1 diabetes | HCC 36–38 by complication | HCC 19–21 by complication (adults 21+ also get add-on HCC 22) | — |
| J45.50–J45.52, J45.42 | Severe persistent asthma; moderate persistent asthma with status asthmaticus | J45.5-: HCC 279; J45.42: no V28 HCC | HCC 161_1 — Severe Asthma | Other asthma codes: HCC 161_2 (Asthma, Except Severe) |
| E43, E44.0 | Severe and moderate protein-calorie malnutrition | No V28 payment HCC | HCC 23 — Protein-Calorie Malnutrition | R62.51 (failure to thrive) maps in neither |
| P07.00–P07.39, P05.0-, Z38.- | Prematurity and low birth weight; light for dates; liveborn infant | No V28 payment HCC | HCCs 242–249 (newborn birthweight and maturity HCCs; age 0 only) | Infant model combines a maturity category with a severity level |
Many HHS-HCC CCs have age splits (for example, a code that maps to one HCC under age 2 and another at age 2 or older). Check the CC Age Split column in DIY Table 3. V24 numbers such as HCC 48, 75, 79, 82, and 85 do not apply in either current model.
Newborn birthweight and maturity HCCs (242–249) apply only in the infant model at age 0. When a hospital bills mother and newborn on one claim, the DIY instructions explain how the newborn and delivery HCCs are separated; follow the payer’s claim rules.
Sources: CMS 2027 Initial ICD-10-CM Mappings (CMS-HCC V28); CMS CY 2024 Rate Announcement, Attachment VI (V28 labels and hierarchies); CMS 2026 Benefit Year HHS-HCC DIY Software Instructions and Tables 3 and 4 (July 31, 2026); FY 2027 ICD-10-CM Tabular List, Index, and Official Guidelines. Verified November 3, 2026.
✍️ CDI Query Templates
The following query templates are designed to be compliant with AHIMA/ACDIS CDI query guidelines — non-leading, multiple-choice, clinician-driven. Queries should be presented as formal documentation requests, not suggestions of a specific answer.
| Scenario | Query Wording (Non-Leading, Multi-Choice) |
|---|---|
| Child with recurrent wheezing, ICS/biologic therapy, no severity specified | “Based on the patient’s documented symptom frequency, nighttime awakenings, activity limitation, FEV1 results, and current controller medication regimen (including [biologic name]), can you clarify the asthma severity classification? Options: (a) Intermittent, (b) Mild persistent, (c) Moderate persistent, (d) Severe persistent, (e) Clinically undetermined.” |
| Child with developmental concerns, behavioral therapy, no specific diagnosis | “The record documents behavioral therapy and developmental concerns. Based on your clinical evaluation, does this patient’s presentation meet criteria for: (a) Autism spectrum disorder (specify severity level if applicable), (b) Intellectual disability (specify degree if applicable), (c) Specific developmental disorder (language/speech/learning), (d) Attention-deficit/hyperactivity disorder, (e) Other specified developmental disorder (F88), (f) Clinically undetermined.” |
| Child with sickle cell disease, hospitalized for pain crisis, type not documented | “This patient was admitted with acute pain in the setting of known sickle cell disease. Based on the clinical presentation and workup, can you identify the type of crisis, if any? Options: (a) Vaso-occlusive pain crisis, (b) Acute chest syndrome, (c) Splenic sequestration, (d) Stroke/CNS crisis, (e) No specific crisis — uncomplicated sickle cell disease, (f) Other (specify), (g) Clinically undetermined.” |
| Child with poor weight gain, low weight-for-age, no malnutrition documented | “The record documents weight-for-age below the 5th percentile with inadequate caloric intake. Based on your clinical assessment, does this patient’s nutritional status represent: (a) No malnutrition, (b) Mild malnutrition (E44.1), (c) Moderate malnutrition (E44.0), (d) Severe protein-calorie malnutrition / marasmus (E43), (e) Failure to thrive without malnutrition (R62.51), (f) Clinically undetermined.” |
| Child with BMI ≥95th percentile on growth chart, no obesity diagnosis documented | “The growth chart documents BMI at or above the 95th percentile for age and sex. Based on your clinical assessment, does this patient have: (a) Overweight (BMI 85th–<95th percentile, Z68.53), (b) Obesity class 1 (BMI ≥95th percentile to <120% of the 95th percentile, E66.811 + Z68.54), (c) Obesity class 2 (BMI ≥120% to <140% of the 95th percentile, E66.812 + Z68.55), (d) Obesity class 3 (BMI ≥140% of the 95th percentile, E66.813 + Z68.56), (e) Overweight/obesity attributable to a secondary medical cause (specify), (f) Clinically undetermined.” |
| Child with intellectual impairment receiving special education, no IQ documented in chart | “The record references special education services and learning difficulties. Based on psychological testing or clinical evaluation, does this patient have: (a) Mild intellectual disability (IQ approximately 50–69, F70), (b) Moderate intellectual disability (IQ approximately 35–49, F71), (c) Severe intellectual disability (IQ approximately 20–34, F72), (d) Profound intellectual disability (IQ <20, F73), (e) Borderline intellectual functioning (IQ 70–84, R41.83), (f) Specific learning disorder (F81.x), (g) Clinically undetermined.” |
| Infant on nusinersen/Zolgensma, SMA type not documented | “This patient is receiving [nusinersen/onasemnogene abeparvovec/risdiplam] for spinal muscular atrophy. Based on the genetic testing and clinical presentation at diagnosis, what is the SMA type? Options: (a) SMA Type I — Werdnig-Hoffmann (G12.0), (b) SMA Type II (G12.1), (c) SMA Type III — Kugelberg-Welander (G12.1), (d) SMA Type IV — adult onset (G12.1), (e) SMA pre-symptomatic (genetic diagnosis only), (f) Clinically undetermined.” |
| Child with epilepsy on multiple AEDs, intractability not documented | “This patient is on [list AEDs] for documented epilepsy. Based on the seizure frequency and response to antiepileptic therapy, is the epilepsy: (a) Controlled/not intractable, (b) Drug-resistant/intractable (poorly controlled despite ≥2 adequate AED trials), (c) Clinically undetermined.” |
For children receiving Medicaid-funded HCBS (Home and Community Based Services) waiver services, the qualifying diagnosis driving the waiver (e.g., G80.x for CP waiver, G12.x for SMA waiver, F84.0 for autism waiver) should be present in the medical record with specificity. The waiver documentation itself is strong evidence to support the qualifying diagnosis — cross-reference with the EHR for coding completeness.
🧑⚕️ Treatments (Clinical)
The following summarizes current evidence-based treatment approaches for major pediatric risk-adjusting conditions. This section provides clinical context to help CDI specialists understand what constitutes active, ongoing management requiring continued diagnosis coding.
Sickle Cell Disease
Management includes hydroxyurea (first-line disease-modifying agent for HbSS/HbSβ⁰), crizanlizumab for vaso-occlusion prevention in eligible patients, L-glutamine, chronic transfusion therapy for stroke prevention, hematopoietic stem cell transplant (HSCT), and gene therapy approaches such as betibeglogene autotemcel/Zynteglo and exagamglogene autotemcel/Casgevy for eligible patients. Voxelotor/Oxbryta is no longer listed as an active treatment because it was voluntarily withdrawn from the market in 2024 due to safety concerns.
Cystic Fibrosis
CFTR modulator therapy has transformed CF management for patients with eligible mutations. Elexacaftor/tezacaftor/ivacaftor (Trikafta/Kaftrio) is approved for patients ≥2 years with at least one F508del allele, achieving sustained FEV1 improvement and dramatic reduction in exacerbations. Airway clearance therapy (ACT), inhaled antibiotics, pancreatic enzyme replacement therapy (PERT), and CF dietitian management remain foundational components. Lung transplant for advanced disease.
Spinal Muscular Atrophy
Disease-modifying therapies include: intrathecal nusinersen (Spinraza, approved all ages and types), IV onasemnogene abeparvovec-xioi (Zolgensma, approved <2 years or <21 kg), and oral risdiplam (Evrysdi, approved ≥2 months). Multidisciplinary care includes respiratory support (non-invasive ventilation, cough assist), nutritional management (gastrostomy tube), and orthopedic management (scoliosis, contractures). Early treatment of pre-symptomatic SMA (newborn screening) has become standard of care in states with NBS programs. (NINDS SMA)
Cerebral Palsy
Multidisciplinary management focuses on maximizing function: physical therapy (PT), occupational therapy (OT), speech-language pathology (SLP), orthotics/AFOs, intrathecal baclofen pump (ITB) for spasticity, selective dorsal rhizotomy (SDR), botulinum toxin injections (BTX-A), and orthopedic surgery (hip reconstruction, hamstring lengthening). Associated epilepsy managed with AEDs; associated ID with educational and behavioral supports.
Autism Spectrum Disorder
Evidence-based interventions include applied behavior analysis (ABA) — the most extensively studied behavioral intervention for ASD — early intensive behavioral intervention (EIBI), speech-language therapy, occupational therapy, social skills training, and family support/caregiver training. Pharmacotherapy (aripiprazole, risperidone) for irritability/self-injurious behavior associated with ASD. No FDA-approved treatment for core ASD symptoms. (AAP Autism Guidance)
Type 1 Diabetes Mellitus
Insulin therapy is required for symptomatic type 1 diabetes (multiple daily injections or continuous subcutaneous insulin infusion/CSII). Continuous glucose monitoring (CGM) and automated insulin delivery should be considered based on the child’s and family’s circumstances, capabilities, and access. Per ADA Standards of Care 2026, A1C goals must be individualized and an A1C of <7% is appropriate for most children and adolescents with diabetes; complication screening should follow current ADA pediatric recommendations.
Severe Persistent Asthma
NHLBI EPR-3/GINA step 5–6 therapy: high-dose ICS + LABA as foundation; add-on biologics for eligible patients ≥6 years (anti-IgE: omalizumab; anti-IL-5: mepolizumab/reslizumab; anti-IL-5Rα: benralizumab; anti-IL-4Rα: dupilumab; anti-TSLP: tezepelumab ≥12 years). Allergen immunotherapy as adjunct. Bronchial thermoplasty not approved for children. Pulmonology/allergy co-management recommended. Asthma action plan, spacer use, avoidance counseling.
🎓 Patient Education / Summary
For CDI and coding teams working with pediatric practices and health plans, the following key takeaways summarize the risk adjustment coding priorities for children with complex chronic conditions:
For Coding and CDI Teams
- Model awareness: Children on ACA exchange plans are subject to HHS-HCC concurrent risk adjustment. Children on Medicaid MCO plans are primarily subject to state CDPS+Rx models. Understanding which model applies determines which code categories drive payment.
- Capture at every encounter: Unlike adult Medicare, HHS-HCC is concurrent — diagnoses from any encounter type (preventive, acute, specialist) during the benefit year count. Document and capture all chronic conditions at every qualifying visit.
- Specificity matters: Non-specific codes (F89, J45.9, G80.9) carry lower or no HCC weight. Query providers to elevate to specific codes (F84.0, J45.50, G80.0) that trigger appropriate HCC assignment.
- Co-morbidities stack: A child with cerebral palsy, epilepsy, and intellectual disability has three independently risk-adjusting diagnoses. Each must be supported by documentation and coded at every encounter where each condition affects management.
- Well-child visit opportunity: The annual well-child exam is the highest-yield encounter for risk adjustment capture because ALL active conditions are typically reviewed. Ensure the claim reflects every chronic condition reviewed during the visit.
- Documentation required: Medication lists and problem lists alone do NOT support risk adjustment claims — only face-to-face encounter notes with supporting clinical documentation. CDI teams should focus on ensuring narrative encounter notes explicitly support each diagnosis code.
Patient / Family Education Points
When preparing patient and family education materials related to complex pediatric conditions that risk-adjust:
- Explain the importance of attending ALL scheduled appointments — primary care, specialist, behavioral health — as each encounter captures the conditions that help ensure adequate resources and coverage for your child’s care.
- Maintain an up-to-date, written diagnosis list including all chronic conditions, medications, and specialists. Bring this to every appointment so the team can document all active conditions.
- Understand that “administrative” diagnoses (the codes on your child’s insurance claims) must reflect what is happening clinically. If your child’s diagnoses have become more or less specific, work with your care team to update documentation.
- For children transitioning from pediatric to adult care (typically age 18–21), ensure that diagnoses are transferred accurately to the new adult provider’s documentation system and that ACA/Medicaid enrollment transitions are managed to preserve continuity of risk-adjustment coding.
- Families of children with CSHCN can contact their health plan’s care management team or state CSHCN program for coordination support. Organizations such as Family Voices and the Association of Maternal and Child Health Programs (AMCHP) provide resources for navigating complex pediatric healthcare.
Pediatric risk adjustment is an evolving area. CMS updates HHS-HCC model coefficients annually through the Notice of Benefit and Payment Parameters (NBPP). State Medicaid programs update their CDPS+Rx models on varying schedules. Coders and CDI professionals should stay current with the applicable model year for each payer to ensure risk-adjustment coding is optimally capturing condition weights for pediatric enrollees.
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2027 ICD-10-CM (effective October 1, 2026) and CPT 2027. All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, AMA CPT, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
CCO Hero
Know someone starting a medical coding career?
Share your personal CCO link. Your friend saves 20% on their first course or practice exam of $100 or more, and you earn 5% cash on their first enrollment over $100.
Become a CCO Hero